Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients (Q39736089)

14 September 2017

title

Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients (English)

1 reference

14 September 2017

0 references

peginterferon alfa-2a

1 reference

1 reference

2

Patrick Marcellin

1 reference

14 September 2017

1

Teerha Piratvisuth

1 reference

14 September 2017

Matei Popescu

3

1 reference

14 September 2017

Hans-Peter Kapprell

series ordinal

4

1 reference

14 September 2017

Vivien Rothe

series ordinal

5

1 reference

14 September 2017

Zhi-Meng Lu

series ordinal

6

1 reference

14 September 2017

publication date

24 June 2011

1 reference

14 September 2017

published in

Hepatology international

1 reference

14 September 2017

volume

7

1 reference

14 September 2017

issue

2

1 reference

14 September 2017

page(s)

429-436

1 reference

https://scigraph.springernature.com/pub.10.1007/s12072-011-9280-0

14 September 2017

exact match

0 references

cites work

High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9280-0

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9280-0

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9280-0

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9280-0

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9280-0

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9280-0

Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9280-0

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9280-0

HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9280-0

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9280-0

Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9280-0

Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9280-0

Expertise of laboratories in viral load quantification, genotyping, and precore mutant determination for hepatitis B virus in a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9280-0

Routine detection and quantification of hepatitis B virus DNA in clinical laboratories: performance of three commercial assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9280-0

Molecular diagnosis of viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9280-0

Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9280-0

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9280-0

Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9280-0

Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9280-0

Assessment of treatment efficacy in HBV infection and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9280-0

Actions of cytokines on the immune response and viral interactions: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9280-0

CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9280-0

Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-α-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9280-0

Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9280-0

Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9280-0

Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9280-0

Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9280-0

Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen-positive patients

21 January 2018

1 reference

12 December 2020

Hepatitis B and hepatitis C in 2009.

1 reference

12 December 2020

Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

12 December 2020

Chronic hepatitis B: update 2009

1 reference

12 December 2020

Hepatitis B virus infection

1 reference

12 December 2020

Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B

1 reference

12 December 2020

10.1007/S12072-011-9280-0

Identifiers

DOI

1 reference

14 September 2017

1 reference